Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NuProtect trial of human cell line-derived recombinant factor VIII in previously untreated severe haemophilia A
ISRCTN50040185Phase 3Completed
- Sponsor
- Octapharma
- Start
- Mar 2013
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label, single-arm trial of simoctocog alfa in hemophilia A, sponsored by Octapharma. Primary endpoint: Immunogenicity. Started Mar 2013; status: completed.
02
Drugs
simoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on ISRCTN50040185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN50040185.